Last reviewed 2026-05-24 · How we verify

Palbociclib plus itraconazole

Pfizer · Phase 1 active Small molecule ✓ Verified May 2026

Palbociclib plus itraconazole is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development. Also known as: Palbociclib (PD-0332991); Itraconazole (Sporanox).

Palbociclib is a medication that has been studied in a clinical trial to investigate its pharmacokinetics when combined with itraconazole. This trial, NCT02131298, was conducted to examine the effect of multiple doses of itraconazole on the single-dose pharmacokinetics of palbociclib in healthy individuals.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Palbociclib plus itraconazole
Also known as	Palbociclib (PD-0332991); Itraconazole (Sporanox)
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Palbociclib plus itraconazole CI brief — competitive landscape report
Palbociclib plus itraconazole updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Palbociclib plus itraconazole

What is Palbociclib plus itraconazole?

Palbociclib plus itraconazole is a Small molecule drug developed by Pfizer.

Who makes Palbociclib plus itraconazole?

Palbociclib plus itraconazole is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is Palbociclib plus itraconazole also known as anything else?

Palbociclib plus itraconazole is also known as Palbociclib (PD-0332991); Itraconazole (Sporanox).

What development phase is Palbociclib plus itraconazole in?

Palbociclib plus itraconazole is in Phase 1.

Manufacturer: Pfizer — full pipeline
Also known as: Palbociclib (PD-0332991); Itraconazole (Sporanox)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing